DOWNLOAD FULL DIGITAL PROGRAM
WEDNESDAYSeptember 4, 2024
THURSDAYSeptember 5, 2024
FRIDAYSeptember 6, 2024
08:00–09:00CONCURRENT
The Sweden Ecosystem: A Route from Concept Creation to Product Delivery
Learn More →
08:00–09:00ROUNDTABLE
Investor Temperature Check: What’s Hot and What’s Not for EU and US Investors
09:15–10:15CONCURRENT
Current Use of iPSC to Fill Unmet Clinical Gaps
09:15–10:15ORAL ABSTRACT
Session 1
CORPORATE PRESENTATIONS
10:15-10:30
Ensuring Precision and Efficiency in Cell and Gene Therapy with the New Cue Manifold Set 5-Lead
Setting Yourself Up for Clinical Success: How do you Increase Your Probability of Clinical Success When Translating from the Lab to GMP?
10:30-10:45
Analysis of DNA Integrity and Stability Using Digital PCR
Innovative Synthetic Peptide-Based Growth Factor Alternatives for Cell Therapy and Regenerative Medicine
10:15-10:45
COFFEE BREAK
10:45-12:15
12:15-13:45
LUNCH
CORPORATE TUTORIAL
12:30-13:00
Unlocking Life-Saving Treatments: Building CAR-T Manufacturing in a New Frontier
13:45–14:45CONCURRENT
Understanding and Developing Your Manufacturing Process – From Phase I to Commercialisation
Innovations in TIL Therapy: Melanoma Trials and Beyond
15:00-16:30
16:30-16:45
Comprehensive Solutions to Ensure Regulatory Compliance in Cell Therapy Workflows, From Bench to Bedside
Leveraging RNAScope to Understand the Spatial Context of Your Cell and Gene Therapies
16:45–17:45CONCURRENT
Breaking Manufacturing Boundaries: Who Will Conquer the Scalability Strategy?
16:45–17:45ROUNDTABLE
Advancing Careers in Cell and Gene Therapy: What Paths Lie Ahead?
18:00-18:30
WELCOME ADDRESS
18:30-20:00
WELCOME RECEPTION
Co-hosted by:
POSTER RECEPTION 1:
iPSC
Regulatory Affairs, Quality Systems, Policy, Ethics, and Patient Access
Exosomes/EVs
Hematopoietic Stem/Progenitor Cells and Engineering
Gene Editing/Gene Therapies
Workforce Development
Tissue Engineering
Embryonic, Organ and Other Tissue Specific Stem Cells
Application of Mesenchymal Stromal Cells – Focusing on the Clinical Indication
Regulatory Considerations for Early Development in the CGT Product Lifecycle
ISCT-ISEV Joint Session: Advancing the Translation of Extracellular Vesicle and Secretome-Based Therapeutics
Standardisation: A Cornerstone of Product Efficacy and Safety
Raw and Starting Material Challenges in CAR-T Manufacturing
Revolutionize Your Cell Therapy Workflows From Identification and Picking of Stem Cells Through to Downstream Manufacturing: Vital Tools for Enhancing Viability, Morphology, Recovery, and Process Efficiency
Maximizing Droplet Digital PCR's Potential for Gene Therapy: Genome Integrity & Capsid Ratio Analysis
CORPORATE PRESENTATION
12:30–13:30
Genetic Engineering Approaches: A Biological Recipe to Gene-Modified Cell Therapies
ATMP Regulatory Interplay: Difficulties in Navigating Quality and Regulatory Standards of Cell-Based Starting Materials in an Era of Regulatory Resilience and Harmonization
13:45–14:45ROUNDTABLE
Professor Privilege: A Win-Win Strategy or an Unrealistic and Economic-Killing Program?
Novel Nanofiber-Based Microcarriers Designed for Improved Upstream Productivity of Viral Vector Biomanufacturing
Cell and Gene Therapy: Optimizing Stable Cell Line Development
Cell and Gene Therapy Cold Chain Management: From Logistics to Product Design
Stem Cell Based Gene Therapy, the Promise of a Life-Long Cure?
16:45–17:45ORAL ABSTRACT
Session 2
17:45-19:15
POSTER RECEPTION 2
Mesenchymal Stem/Stromal Cells
Immunotherapy (CAR-T, T Reg, NK Cells etc.)
Process Development and Manufacturing
Improving AAV Vector Designs: New Concepts for Gene Therapy Translation
Investment and Reimbursement: How to Bring Europe to the Forefront of the Sector
09:15–10:15ROUNDTABLE
Potency Assays: From Assay Design to Clinical Validation
Session 3
Overcoming Cell Therapy Manufacturing Hurdles with Cutting-Edge GMP Solutions
Rapid Sterility Testing for CGT Products
11:00–12:00ROUNDTABLE
Challenges in Cell & Gene Therapy: Role of Related Scientific Societies, Harmonization and Position Papers in Scientific Journals
Is Our Infrastructure Ready for the Future of ATMP Development?